Key Dates

Related Announcements

June 29, 2023 - Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). See NOFO PA-23-189.

Issued by

National Institute of General Medical Sciences (NIGMS)

Purpose

The purpose of this Notice is to inform NIGMS awardees of expanded program eligibility for diversity supplements. Applications must be submitted to PA-23-189 “Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)" or a subsequent reissuance. 

Effective immediately, NIGMS is expanding eligibility to include applications from Program Directors/Principal Investigators (PDs/PIs) of parent awards from the following programs: Support for Research Excellence (SuRE, R16), Centers of Biomedical Research Excellence (COBRE Phase 1 and 2, P20), IDeA Networks of Biomedical Research Excellence (INBRE, P20), Institutional Development Award (IDeA) Networks for Clinical and Translational Research (IDeA-CTR, U54), and Native American Research Centers for Health (NARCH, S06). 

For more information about this change to eligibility, please see NIGMS Diversity Supplements—Expanded Program Eligibility.

Additional information about application and submission procedures, as well as eligibility and funding priorities can be found on the Diversity Program webpage. PDs/PIs of eligible individuals are strongly encouraged to discuss potential diversity supplement requests, proposed training and career development plans, and the supplement application process with their program officer before applying. 

Inquiries

Please direct all inquiries to:

Shakira Nelson, Ph.D. and  Zuzana Justinova, M.D., Ph.D.
National Institute of General Medical Sciences (NIGMS)
Email: [email protected]